113 related articles for article (PubMed ID: 15986591)
1. Preoperative second-line chemotherapy induces objective responses in primary breast cancer.
Wenzel C; Locker GJ; Bartsch R; Pluschnig U; Hussian D; Zielinski CC; Rudas M; Gnant MF; Jakesz R; Steger GG
Wien Klin Wochenschr; 2005 Jan; 117(1-2):48-52. PubMed ID: 15986591
[TBL] [Abstract][Full Text] [Related]
2. Docetaxel followed by fluorouracil/epirubicin/cyclophosphamide as neoadjuvant chemotherapy for patients with primary breast cancer.
Iwata H; Sato N; Masuda N; Nakamura S; Yamamoto N; Kuroi K; Kurosumi M; Tsuda H; Akiyama F; Ohashi Y; Toi M
Jpn J Clin Oncol; 2011 Jul; 41(7):867-75. PubMed ID: 21719750
[TBL] [Abstract][Full Text] [Related]
3. Neoadjuvant 5-fluorouracil, epirubicin and cyclophosphamide chemotherapy followed by docetaxel in refractory patients with locally advanced breast cancer.
Heller W; Mazhar D; Ward R; Sinnett HD; Lowdell C; Phillips R; Shousha S; Fayaz A; Palmieri C; Coombes RC
Oncol Rep; 2007 Jan; 17(1):253-9. PubMed ID: 17143506
[TBL] [Abstract][Full Text] [Related]
4. Taxane-based chemotherapy enhances response to neoadjuvant treatment for stage II and III breast cancer.
Andrade JM; Carrara HH; Pimentel FF; Marana HR; Macchetti AH; Mouro LR; Zola FE; Tiezzi DG
Med Oncol; 2011 Dec; 28 Suppl 1():S65-9. PubMed ID: 20953738
[TBL] [Abstract][Full Text] [Related]
5. Neoadjuvant triweekly nanoparticle albumin-bound paclitaxel followed by epirubicin and cyclophosphamide for Stage II/III HER2-negative breast cancer: evaluation of efficacy and safety.
Shimada H; Ueda S; Saeki T; Shigekawa T; Takeuchi H; Hirokawa E; Sugitani I; Sugiyama M; Takahashi T; Matsuura K; Yamane T; Kuji I; Hasebe T; Osaki A
Jpn J Clin Oncol; 2015 Jul; 45(7):642-9. PubMed ID: 25989989
[TBL] [Abstract][Full Text] [Related]
6. Phase II study of preoperative sequential FEC and docetaxel predicts of pathological response and disease free survival.
Toi M; Nakamura S; Kuroi K; Iwata H; Ohno S; Masuda N; Kusama M; Yamazaki K; Hisamatsu K; Sato Y; Kashiwaba M; Kaise H; Kurosumi M; Tsuda H; Akiyama F; Ohashi Y; Takatsuka Y;
Breast Cancer Res Treat; 2008 Aug; 110(3):531-9. PubMed ID: 17879158
[TBL] [Abstract][Full Text] [Related]
7. Interim analysis of a phase II trial of cyclophosphamide, epirubicin and 5-fluorouracil (CEF) followed by docetaxel as preoperative chemotherapy for early stage breast carcinoma.
Iwata H; Nakamura S; Toi M; Shin E; Masuda N; Ohno S; Takatsuka Y; Hisamatsu K; Yamazaki K; Kusama M; Kaise H; Sato Y; Kuroi K; Akiyama F; Tsuda H; Kurosumi M;
Breast Cancer; 2005; 12(2):99-103. PubMed ID: 15858439
[TBL] [Abstract][Full Text] [Related]
8. Epidoxorubicin and paclitaxel as primary chemotherapy for T > 3 cm and T4 breast cancer patients.
Bellino R; Cortese P; Danese S; De Sanctis C; Durando A; Genta F; Grio R; Giardina G; Katsaros D; Massobrio M; Richiardi G; Vicelli R
Anticancer Res; 2000; 20(6C):4825-8. PubMed ID: 11205227
[TBL] [Abstract][Full Text] [Related]
9. Toxicity of dual HER2-blockade with pertuzumab added to anthracycline versus non-anthracycline containing chemotherapy as neoadjuvant treatment in HER2-positive breast cancer: The TRAIN-2 study.
van Ramshorst MS; van Werkhoven E; Honkoop AH; Dezentjé VO; Oving IM; Mandjes IA; Kemper I; Smorenburg CH; Stouthard JM; Linn SC; Sonke GS;
Breast; 2016 Oct; 29():153-9. PubMed ID: 27498129
[TBL] [Abstract][Full Text] [Related]
10. Preoperative therapy with epidoxorubicin and docetaxel plus trastuzumab in patients with primary breast cancer: a pilot study.
Wenzel C; Hussian D; Bartsch R; Pluschnig U; Locker GJ; Rudas M; Gnant MF; Jakesz R; Zielinkski CC; Steger GG
J Cancer Res Clin Oncol; 2004 Jul; 130(7):400-4. PubMed ID: 15168107
[TBL] [Abstract][Full Text] [Related]
11. [Neoadjuvant treatment for locally advanced breast cancer. Comparison of two schemes based on docetaxel-epirubicin vs. 5-fluorouracil-epirubicin-cyclophosphamide].
Cortés-Flores AO; Morgan-Villela G; Castro-Cervantes JM; Vázquez-Camacho G; Fuentes-Orozco C; González-Ojeda A
Cir Cir; 2008; 76(1):23-8. PubMed ID: 18492416
[TBL] [Abstract][Full Text] [Related]
12. [Clinical phase II-evaluation of neoadjuvant, cytostatic combination chemotherapy with docetaxel and epidoxorubicin in female breast cancer patients (T1-4, N0-2, M0)].
Wenzel C; Schmidinger M; Locker GJ; Taucher S; Gnant M; Jakesz R; Steger GG
Wien Klin Wochenschr; 1999 Oct; 111(20):843-50. PubMed ID: 10586489
[TBL] [Abstract][Full Text] [Related]
13. Prognostic factors in operable breast cancer treated with neoadjuvant chemotherapy: towards a quantification of residual disease.
Mombelli S; Kwiatkowski F; Abrial C; Wang-Lopez Q; de Boissieu P; Garbar C; Bensussan A; Curé H
Oncology; 2015; 88(5):261-72. PubMed ID: 25573741
[TBL] [Abstract][Full Text] [Related]
14. Correlation between magnetic resonance imaging and histopathological tumor response after neoadjuvant chemotherapy in breast cancer.
Nicoletto MO; Nitti D; Pescarini L; Corbetti F; Mencarelli R; Cappetta A; Galligioni A; Pogliani C; Marchet A; Bozza F; Ghiotto C; Griggio L; Zavagno G; Donach ME; Di Maggio C
Tumori; 2008; 94(4):481-8. PubMed ID: 18822682
[TBL] [Abstract][Full Text] [Related]
15. Monotherapy with paclitaxel as third-line chemotherapy against anthracycline-pretreated and docetaxel-refractory metastatic breast cancer.
Kinoshita J; Haga S; Shimizu T; Imamura H; Watanabe O; Nagumo H; Utada Y; Okabe T; Kimura K; Hirano A; Kajiwara T
Breast Cancer; 2002; 9(2):166-9. PubMed ID: 12016397
[TBL] [Abstract][Full Text] [Related]
16. Current strategy for triple-negative breast cancer: appropriate combination of surgery, radiation, and chemotherapy.
Yagata H; Kajiura Y; Yamauchi H
Breast Cancer; 2011 Jul; 18(3):165-73. PubMed ID: 21290263
[TBL] [Abstract][Full Text] [Related]
17. Neoadjuvant vinorelbine-capecitabine versus docetaxel-doxorubicin-cyclophosphamide in early nonresponsive breast cancer: phase III randomized GeparTrio trial.
von Minckwitz G; Kümmel S; Vogel P; Hanusch C; Eidtmann H; Hilfrich J; Gerber B; Huober J; Costa SD; Jackisch C; Loibl S; Mehta K; Kaufmann M;
J Natl Cancer Inst; 2008 Apr; 100(8):542-51. PubMed ID: 18398097
[TBL] [Abstract][Full Text] [Related]
18. Neoadjuvant treatment with paclitaxel and epirubicin in invasive breast cancer: a phase II study.
Sarid D; Ron IG; Sperber F; Stadler Y; Kahan P; Kovner F; Ben-Yosef R; Marmor S; Grinberg Y; Maimon N; Weinstein J; Yaal-Hahoshen N
Clin Drug Investig; 2006; 26(12):691-701. PubMed ID: 17274676
[TBL] [Abstract][Full Text] [Related]
19. Preoperative chemotherapy with epidoxorubicin, docetaxel and capecitabine plus pegfilgrastim in patients with primary breast cancer.
Wenzel C; Bartsch R; Locker GJ; Hussian D; Pluschnig U; Sevelda U; Gnant MF; Jakesz R; Zielinski CC; Steger GG
Anticancer Drugs; 2005 Apr; 16(4):441-5. PubMed ID: 15746581
[TBL] [Abstract][Full Text] [Related]
20. High pathologic complete response in HER 2-positive locally advanced breast cancer after primary systemic chemotherapy with weekly docetaxel and epirubicin.
Chen SC; Chang HK; Lin YC; Hsueh S; Cheung YC; Leung WM; Tsai CS; Lo YF; Tsai HP; Shen SC; Chen MF
Jpn J Clin Oncol; 2008 Feb; 38(2):99-105. PubMed ID: 18270380
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
